rs4803217

A comprehensive review of IL28B gene polymorphisms and their impact on drug responses across multiple conditions. The review discusses how three major IL28B SNPs (rs12979860, rs8099917, rs12980275) and seven additional polymorphisms predict treatment response to interferon-based therapies for chronic hepatitis C, hepatitis B, and myeloproliferative neoplasms. IL28B genotypes, particularly the favorable CC genotype at rs12979860 and TT genotype at rs8099917, are associated with higher sustained virologic response (SVR) rates in HCV treatment, with effect sizes showing 3-4.5 fold differences in relapse risk between genotypes.

This study examined IL-28B genetic variation and spontaneous hepatitis C virus clearance using multiple- and single-source cohorts. IL-28B protective haplotypes were strongly associated with HCV clearance (OR=2.1 [95% CI 1.6-3.0] in multiple-source cohort, OR=3.9 [95% CI 1.5-10.2] in single-source cohort; P=6×10⁻⁹). The protective haplotypes were in perfect linkage (r²=1.0) with the nonsynonymous coding variant rs8103142, and homozygosity for the rs12979860 C allele predicted the protective haplotype status.